Clinical trials: Crohn Disease
Crohn's Disease, Ulcerative Colitis (UC)
Expanded Access to Risankizumab
This is an expanded access program (EAP) for eligible participants with Crohn's Disease (CD). This program is designed to provide access to risankizumab, prior to approval by the local regulatory agency, to patients with the…
- Trial name
- NCT03914261
- Testing
- Risankizumab
- Sponsor
- AbbVie
Crohn's Disease
Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease
The purpose of this study is to determine the safety and efficacy of natalizumab in individuals diagnosed with moderate to severely active Crohn's disease.
- Trial name
- NCT00032786
- Testing
- natalizumab
- Sponsor
- Biogen
Colitis, Ulcerative, Crohn's Disease
A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's Disease
The main aim of the study is to check for long-term side effects of Vedolizumab Subcutaneous (also known as Vedolizumab SC) in people with ulcerative colitis (UC) and Crohn's disease (CD).
- Trial name
- NCT02620046
- Testing
- Vedolizumab SC
- Where
- 301 sites in United States, Argentina and 31 more
- Volunteers
- 746 people
- Sponsor
- Takeda
Crohn's Disease
Remission in Subjects With Crohn's Disease, 1 Year Phase
The objectives were: (1) To demonstrate the efficacy of adalimumab in the maintenance of clinical remission up to 56 weeks in participants with Crohn's disease who participated in NCT00055523; (2) To delineate the safety of…
- Trial name
- CLASSICII (NCT00055497)
- Testing
- DB adalimumab 40 mg eow, DB adalimumab 40 mg ew, OL adalimumab 40 mg
- Where
- 43 sites in United States
- Volunteers
- 276 people
- Sponsor
- Abbott
Crohn Disease
A Long Term Extension Trial of BI 655066/ABBV-066 (Risankizumab), in Patients With Moderately to Severely Active Crohn's Disease
The primary objective of the study was to investigate long-term safety of risankizumab (BI 655066/ABBV-066) in participants with moderately to severely active Crohn's disease who showed a clinical response or remission on…
- Trial name
- NCT02513459
- Testing
- Risankizumab 600 mg IV, Risankizumab 180 mg SC
- Where
- 28 sites in United States, Belgium and 7 more
- Volunteers
- 65 people
- Sponsor
- AbbVie
Inflammatory Bowel Disease
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of MT-1303 in Subjects With Inflammatory Bowel Disease
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of a single oral dose of MT-1303 in subjects with inflammatory bowel disease.
- Trial name
- NCT01666327
- Testing
- MT-1303
- Where
- United Kingdom
- Volunteers
- 18 people
- Sponsor
- Tanabe Pharma Corporation
Crohn Disease
A Study of TAK-018 in Preventing the Recurrence of Crohn's Disease After Surgery
The main aim is to see if TAK-018 reduces the recurrence of intestinal inflammation after abdominal resection surgery in adults with Crohn's disease.
- Trial name
- NCT03943446
- Testing
- TAK-018
- Where
- 41 sites in United States, Austria and 3 more
- Volunteers
- 34 people
- Sponsor
- Takeda
Crohn Disease
A Pharmacokinetic Study of Ustekinumab in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
The purpose of this study is to evaluate the pharmacokinetics (PK) of ustekinumab in subjects from 2 through less than (<) 18 years old in the USA, or 6 through less than (<) 18 years old in other countries and determine if it is…
- Trial name
- STELARA (NCT02968108)
- Testing
- Ustekinumab
- Where
- 26 sites in United States, Belgium and 4 more
- Volunteers
- 45 people
- Sponsor
- Janssen Research & Development, LLC
Crohn's Disease
Study of Nitazoxanide Tablets in the Treatment of Mild to Moderate Active Crohn's Disease
The primary objective of this study is to evaluate the efficacy and safety of nitazoxanide compared to a placebo in reducing the signs and symptoms of mild to moderate active Crohn's disease in adults.
- Trial name
- NCT00130390
- Testing
- Nitazoxanide
- Where
- 13 sites in United States
- Volunteers
- 98 people
- Sponsor
- Romark Laboratories L.C.
Inflammatory Bowel Diseases, Colitis, Ulcerative
A Study of Kynteles Injection (Vedolizumab) in Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease or Chronic Pouchitis
In this study, participants with ulcerative colitis or Crohn's disease or pouchitis will be treated with Kynteles injection (Vedolizumab) according to their clinic's standard practice.
- Conditions
- Inflammatory Bowel Diseases, Colitis, Ulcerative, Crohn Disease
- Trial name
- NCT04799496
- Where
- 43 sites in South Korea
- Volunteers
- 688 people
- Sponsor
- Takeda
Inflammatory Bowel Diseases, Blau Syndrome
Phase 1 Study to Investigate OD-07656 in Healthy Adult Participants
First-in-human study to provide an assessment of the safety, tolerability, pharmacokinetics (PK), including food effects and a drug-drug interaction, and pharmacodynamics (PD) of OD-07656 after administration of ascending single…
- Conditions
- Inflammatory Bowel Diseases, Blau Syndrome, Crohn Disease, Ulcerative Colitis
- Trial name
- NCT06206811
- Testing
- OD-07656
- Where
- Australia
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- Odyssey Therapeutics, Inc.
Crohn Disease
Dose Finding Study of BIRB 796 BS in Patients With Moderate to Severe Crohn's Disease
The primary objective of this extension study was to obtain long-term safety data for BIRB 796 BS in patients with moderate to severe Crohn's disease after 26 weeks of treatment.
- Trial name
- NCT02209792
- Testing
- BIBR 796 BS, 5 mg, BIBR 796 BS, 20 mg
- Volunteers
- 284 people
- Sponsor
- Boehringer Ingelheim
Crohn's Disease
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most frequently affecting the bowels.
- Trial name
- Target CD (NCT06548542)
- Testing
- Risankizumab, Lutikizumab, Trosunilimab
- Where
- 255 sites in United States, Austria and 31 more
- Volunteers
- 590 people
- Sponsor
- AbbVie
Crohn's Disease
Effects of Adalimumab on Mucosal Healing in Subjects With Crohn's Disease Involving the Colon
The goal of this study was to test whether adalimumab can induce mucosal healing in subjects with moderate to severe ileocolonic Crohn's Disease.
- Trial name
- NCT00348283
- Testing
- adalimumab
- Where
- 21 sites in United States, Austria and 6 more
- Volunteers
- 135 people
- Sponsor
- Abbott
Crohn Disease
A Study Testing How BI 655130 Works in Patients With Fistulizing Crohn's Disease
This is a study in adults with Crohn's Disease who also have fistulas near the anus. The study has 2 parts. The first part is to find out more about what causes the fistulas.
- Trial name
- NCT03752970
- Testing
- Spesolimab
- Where
- 10 sites in Austria, Belgium and 6 more
- Volunteers
- 27 people
- Sponsor
- Boehringer Ingelheim
Hepatosplenic T-Cell Lymphoma
A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL)
This study is designed to collect tissue samples from the biopsy specimen that was used to diagnose hepatosplenic T-cell lymphoma (HSTCL), additional patient information, and if possible, to obtain additional samples including a…
- Trial name
- NCT01804166
- Testing
- Infliximab, Golimumab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Janssen Scientific Affairs, LLC
Crohn's Disease
Evaluation of Efficacy and Safety of MEDI2070 in Patients With Active, Moderate-to-severe Crohn's Disease.
The study is designed to evaluate the clinical efficacy and safety of MEDI2070 as compared to placebo. Investigational product will be administered as intravenous infusion in double-blind period, and as a subcutaneous injection…
- Trial name
- NCT01714726
- Testing
- MEDI2070
- Where
- 80 sites in United States, Canada and 7 more
- Volunteers
- 121 people
- Sponsor
- AstraZeneca
Crohn's Disease
A Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Intravenous (IV) Infusion and Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Crohn's Disease
Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. CD may cause tiredness, loose stools with or without bleeding, abdominal pain, weight loss, and fever.
- Trial name
- AIM-CD (NCT05068284)
- Testing
- ABBV-154
- Where
- 166 sites in United States, Australia and 22 more
- Volunteers
- 176 people
- Sponsor
- AbbVie